Track Biotech Acquisition's total liabilities ($13M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Biotech Acquisition posts a total liabilities of $13M as of September 2022. That compares with $21M in the prior-year period — down 35.7% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
In the prior comparable period, Biotech Acquisition's total liabilities was $21M. The latest reading is $13M — a 35.7% year-over-year decrease (period ending September 2022). Use the history and growth charts on this page for a longer lookback.
Total Liabilities is one piece of Biotech Acquisition's financial statement story. At $13M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.
Context for BIOT's total liabilities usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Biotech Acquisition's other metric pages and overview cover the third.